Supernus Pharmaceuticals inc (SUPN)
Sector • Healthcare Industry • Major Pharmaceutical Preparations |
Industry • Major Pharmaceutical Preparations |
Sector • Healthcare |
The Major Pharmaceutical Preparations company declared a superb advance, in the October to December 31 2022 time-frame
company delivered operating surplus of $46.124 million
Published Mar 13 2023
CSIMarket Team / CSIMarket.com
company announced EPS of $1.04 and Revenue of $579.78 million in the most recent fiscal period, SUPNs' EPS plummeted $1.04 per share, versus $2.05 eps, earned in the same time-frame a year before, although SUPN saw its Revenue rise by 63.18 % in the same period.
Opposing to the revenue improved by 15.086 % from $579.78 million and income improved by 6.12 % from $0.98 per share.
Net income of $60.711 million in the most recent fiscal period fell by -45.3 % from $110.993 million in the corresponding period a year before. Supernus Pharmaceuticals Inc shifted it's focus on improving sales in the most recent fiscal period, as a result net margin eased to 9.1%.
Operating earnings, fell -68.07% to $46.124 million, squeezing Supernus Pharmaceuticals Inc 's operating margin to 6.91%, from 35.33% in the.
Supernus Pharmaceuticals Inc is expected to report next financial recent numbers on May 11, 2023.
Opposing to the revenue improved by 15.086 % from $579.78 million and income improved by 6.12 % from $0.98 per share.
Net income of $60.711 million in the most recent fiscal period fell by -45.3 % from $110.993 million in the corresponding period a year before. Supernus Pharmaceuticals Inc shifted it's focus on improving sales in the most recent fiscal period, as a result net margin eased to 9.1%.
Operating earnings, fell -68.07% to $46.124 million, squeezing Supernus Pharmaceuticals Inc 's operating margin to 6.91%, from 35.33% in the.
Supernus Pharmaceuticals Inc is expected to report next financial recent numbers on May 11, 2023.